Polymeric Materials in Medication

1. Front Matter

   Pages i-viii

   PDF

2. Methodologies in Polymeric Medication

   • Charles G. Gebelein

   Pages 1-9

3. Tissue/Material Interactions of Biomedical Polymers

   • R. E. Marchant, J. M. Anderson

   Pages 11-26

4. Polymer-Controlled Drug Delivery Systems: Science and Engineering

   • Yie W. Chien

   Pages 27-46

5. Fibrous Delivery Systems for Antimicrobial Agents

   • R. L. Dunn, J. W. Gibson, B. H. Perkins, J. Max Goodson, L. E. Laufe

   Pages 47-59

6. Evaluation of Membrane Suitability in Transdermal Drug Delivery

   • James L. Gaskill, Pramod P. Sarpotdar, Robert P. Giannini

   Pages 61-71

7. Diffusion Controlled Release of Drugs from Coated Drug Polymer Complex

   • Y. Raghunathan, L. Amsel, O. Hinsvark, K. Rotenberg

   Pages 73-78

8. Kinetics of Drug Release from Glassy Polymers: Effect of Initially Nonuniform Drug Distribution

   • Ping I. Lee

   Pages 79-85

9. The Role of Polymer Matrix Structure and Interparticle Interaction in Diffusion-Limited Drug Release

   • Anna C. Balazs, Daniel F. Calef, J. M. Deutch, Ronald A. Siegel, Robert Langer

   Pages 87-101

10. Polymeric Anticancer Agents — An Overview

    • Malay Ghosh, Sukumar Maiti

    Pages 103-114

11. The Controlled Release of 5-Fluorouracil from Acrylate Copolymers of 1-(N-2-Ethylmethacrylcarbamoyl)-5-Fluorouracil Monomer

    • Robert R. Hartsough, Charles G. Gebelein

    Pages 115-124

12. Halogenated Nucleic Acids: Biochemical and Biological Properties of Fluorinated Polynucleotides

    • J. L. Alderfer, R. E. Loomis, S. D. Soni, M. Sharma, R. Bernacki, R. Hughes Jr.

    Pages 125-138

13. Toxicity and Tissue Distribution of MVE-2 in the Dog After Intravenous and Intraperitonal Administration

    • J. R. Baldwin, R. A. Carrano, A. R. Imondi, J. D. Iuliucci, L. M. Hagerman

    Pages 139-149

14. Transformation of Mouse Fibroblast (T3T) Cells Employing the Oncogenic Simian Virus 40 (SV40) for Evaluation of Anticancer Compounds

    • David J. Giron, Mark J. Espy, Charles E. Carraher Jr.

    Pages 151-163

15. Screening of Platinum II Polymines as Antitumor Drugs Employing Cell Differation of Normal and Transformed 3T3 Cells

    • David J. Giron, Mark J. Espy, Charles E. Carraher Jr., Isabel Lopez

    Pages 165-171

16. Polymeric Derivatives of cis-Dichlorodiammineplatinum II Analogs Based on Polyvinylamine-co-vinylsulfonate as Model Carriers in the Drug Delivery System

    • Charles E. Carraher Jr., Claredine M. Ademu-John, John J. Fortman, David J. Giron, Carolyn Turner, Raymond Linville

    Pages 173-181

17. Soluble Excipients Assisting Dissolution of Drugs: Importance of Amorphous State

    • Josef Pitha

    Pages 183-190

18. Polymeric Hydroxamic Acids for Iron Chelators Therapy

    • A. Winston, D. V. P. R. Varaprasad, J. J. Metterville, H. Rosenkrantz

    Pages 191-196

19. Oxygen Species Chemistry of Osmium Carbohydrate Polymers

    • C. C. Hinckley, M. A. Islam, P. A. Kibala, J. L. Skosey, D. C. Chow, S. Liu

    Pages 197-210

20. Synthetic Polymeric Inducers of Interferon

    • Ernest M. Hodnett

    Pages 211-226

The art of using chemical agents for medication dates back into antiquity, although most of the earliest examples used plants, herbs, and other natural materials. The old Egyptian medical papyri, which date from before 1400 B. C. , contain dozens of examples of such medicinal plants and animal extracts. In the Old Testament of the Bible, we can find references to using oil to soften the skin and sores (Isaiah 1:6), the use of tree leaves for medicine (Ezekiel 47:12) and various medical balms (Jeremiah 8:22). Not all these recipes were effective in curing the ailments for which they were used and sometimes the treatment was worse than the disease. Nevertheless, the art of using chemical derived agents for medicines continued to develop and received great impetus during the present century with the rise of synthetic organic chemistry. One of the most vexing problems has always been to achieve specifici­ ty with the medications. While some medical agents do indeed possess a relatively high degree of specificity, most agents are far more systemic than would be desired. Much of the research efforts to correct this deficiency has centered on modifying the chemical agents themselves. Unfortunately, there are severe limitations in this approach since minor modifications often drastically affect the therapeutic activity and can even render the drug completely ineffective, or worse.

• cancer
• chemistry
• drug
• drug delivery
• immunomodulation
• interferon
• kinetics
• research
• toxicity

• Youngstown State University, Youngstown, USA

  Charles G. Gebelein

• Florida Atlantic University, Boca Raton, USA

  Charles E. Carraher

Policies and ethics